aprepitant + olanzapine + palonosetron

This is a non-branded, three-drug combination regimen consisting of aprepitant, olanzapine, and palonosetron. It is used primarily for the prevention and management of chemotherapy-induced nausea and vomiting (CINV), especially in patients receiving highly emetogenic chemotherapy. - **Aprepitant** is a neurokinin 1 (NK1) receptor antagonist that blocks the action of substance P, a key mediator in the vomiting reflex. - **Olanzapine** is an atypical antipsychotic with antiemetic properties attributed to its antagonism at multiple neurotransmitter receptors involved in emesis, including dopamine D2 and serotonin 5-HT2 receptors. - **Palonosetron** is a second-generation serotonin (5-HT3) receptor antagonist that prevents both acute and delayed CINV by blocking serotonin activity centrally and peripherally[1][4]. This combination may be used as an alternative to regimens containing corticosteroids like dexamethasone for patients where steroid use should be minimized or avoided[2]. The regimen has been studied in clinical trials for efficacy against CINV.